Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
598.76B
Market cap598.76B
Price-Earnings ratio
22.52
Price-Earnings ratio22.52
Dividend yield
2.09%
Dividend yield2.09%
Average volume
9.92M
Average volume9.92M
High today
$251.71
High today$251.71
Low today
$246.87
Low today$246.87
Open price
$248.74
Open price$248.74
Volume
9.04M
Volume9.04M
52 Week high
$251.71
52 Week high$251.71
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

Johnson & Johnson(JNJ) stock is priced at $249.10, giving the company a market capitalization of 598.76B. It carries a P/E multiple of 22.52 and pays a dividend yield of 2.1%.

During the trading session on 2026-03-03, Johnson & Johnson(JNJ) shares reached a daily high of $251.71 and a low of $246.87. At a current price of $249.10, the stock is +0.9% higher than the low and still -1.0% under the high.

Trading volume for Johnson & Johnson(JNJ) stock has reached 9.04M, versus its average volume of 9.92M.

The stock's 52-week range extends from a low of $141.50 to a high of $251.71.

The stock's 52-week range extends from a low of $141.50 to a high of $251.71.

JNJ News

TipRanks 3d
JPMorgan Equity Premium Income ETF Sees Strong Inflows

JPMorgan Equity Premium Income ETF ( $JEPI ) has risen by 1.23% in the past week. It has experienced a 5-day net inflow of $325.13 million. This is due, in par...

Nasdaq 3d
Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap?

Key Points Middleby built both businesses through acquisitions, and the roll-up strategy is expected to continue. The commercial foodservice segment anchors t...

Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap?
TipRanks 3d
Boeing, Walmart, Coca-Cola, Ford, J&J: Insider Moves Exposed

Insiders have been trading these 5 stocks: ((BA)), ((WMT)), ((KO)), ((F)) and ((JNJ)). Here is a breakdown of their recent trades and their value. EVP and Chie...

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
35.7%
Sell
7.1%

More JNJ News

Simply Wall St 4d
Jury Talc Verdict Puts Johnson And Johnson Valuation In Sharp Focus

A Philadelphia jury found Johnson & Johnson (NYSE:JNJ) liable in a talc ovarian cancer lawsuit. The verdict is the first plaintiff win in Philadelphia’s talc m...

Jury Talc Verdict Puts Johnson And Johnson Valuation In Sharp Focus
TipRanks 5d
J&J posts early phase 1b results for pasritamig in metastatic prostate cancer

Johnson & Johnson announced preliminary results from a Phase 1b study evaluating pasritamig, a first-in-class bispecific T-cell engaging antibody, in combinatio...

Nasdaq 5d
April 10th Options Now Available For Johnson & Johnson

Investors in Johnson & Johnson (Symbol: JNJ) saw new options begin trading today, for the April 10th expiration. At Stock Options Channel , our YieldBoost formu...

April 10th Options Now Available For Johnson & Johnson
Simply Wall St 6d
Will Philadelphia Talc Verdict Reshape Johnson & Johnson's Legal Overhang and Earnings Resilience Narrative?

Recently, a Philadelphia jury found Johnson & Johnson liable in a talc ovarian cancer case, awarding US$250,000 in compensatory and punitive damages over allege...

Will Philadelphia Talc Verdict Reshape Johnson & Johnson's Legal Overhang and Earnings Resilience Narrative?
TipRanks 6d
Johnson & Johnson submits sBLA to FDA for approval of Imaavy

Johnson & Johnson announced the submission of a supplemental Biologics License Application to the U.S. FDA seeking approval of Imaavy as the first-ever treatmen...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.